natgillin/translations-raw huggingface dataset:
The apparent terminal half-life (t1/2) (expressed as mean ± standard deviation) was 10.6 ± 2.13 hours and 13.1 ± 3.28 hours for the 100 mg and 300 mg doses, respectively. 
Prividno završno poluvrijeme (t1/2) (izraženo kao srednja vrijednost ± standardna devijacija) bilo je 10,6 ± 2,13 sati i 13,1 ± 3,28 sati za dozu od 100 mg odnosno od 300 mg.
• efavirenz or ritonavir (a medicine used to treat HIV infection) 
• efavirenz ili ritonavir (lijek koji se uzima za liječenje HIV infekcije)
Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment. 
Vezanje na proteine nije značajno promijenjeno u bolesnika s oštećenjem bubrega ili jetre.
Plasma Cmax and AUC of canagliflozin increased in a dose-proportional manner from 50 mg to 300 mg. 
Cmax i AUC kanagliflozina u plazmi povisili su se proporcionalno dozi od 50 mg do 300 mg.
• blood tests may show changes related to kidney function (creatinine or urea) or potassium 
• krvne pretrage mogu pokazati promjene povezane s bubrežnom funkcijom (kreatinin ili urea) ili kalijem
Adverse reactions reported from world-wide postmarketing use of canagliflozin are also included in this tabulation. 
Nuspojave prijavljene tijekom primjene kanagliflozina nakon stavljanja u promet u svijetu su također uključene u ovu tablicu.
In in vitro studies, canagliflozin neither inhibited cytochrome P450 CYP1A2,CYP2A6, CYP2C19, CYP2D6, or CYP2E1, CYP2B6, CYP2C8, CYP2C9, nor induced CYP1A2, CYP2C19, CYP2B6, CYP3A4 at higher than therapeutic concentrations. 
U in vitro ispitivanjima, pri koncentracijama višim od terapijskih, kanagliflozin niti je inhibirao citokrome P450 CYP1A2,CYP2A6, CYP2C19, CYP2D6, ili CYP2E1, CYP2B6, CYP2C8, CYP2C9, niti je inducirao CYP1A2, CYP2C19, CYP2B6, CYP3A4.
Among male patients taking canagliflozin, 0.9% had more than one infection. 
Među muškim bolesnicima koji uzimaju kanagliflozin 0,9% imalo je više od jedne infekcije.
To control your diabetes, you still need to follow the advice about diet and exercise from your doctor, pharmacist or nurse. 
Kako biste kontrolirali svoju šećernu bolest i dalje morate slijediti savjete o dijeti i tjelovježbi koje ste dobili od svog liječnika, ljekarnika ili medicinske sestre.
5.3 Pre-clinical safety data 
5.3 Neklinički podaci o sigurnosti primjene
These decreases in exposure to canagliflozin may decrease efficacy. 
Ovo smanjenje izloženosti kanagliflozinu može smanjiti djelotvornost.
CYP3A4-mediated (oxidative) metabolism of canagliflozin is minimal (approximately 7%) in humans. 
Metabolizam kanagliflozina posredovan s CYP3A4 (oksidativni) u ljudi je minimalan (približno 7%).
• dabigatran (blood thinner medicine that lowers the risk of blood clot formation). 
• dabigatran (lijek za razrjeđivanje krvi koji smanjuje rizik za formiranje krvnog ugruška).
This effect at the 300 mg dose of canagliflozin may, in part, be due to local inhibition of intestinal SGLT1 (an important intestinal glucose transporter) related to transient high concentrations of canagliflozin in the intestinal lumen prior to medicinal product absorption (canagliflozin is a low potency inhibitor of the SGLT1 transporter). 
Ovaj učinak pri dozi od 300 mg kanagliflozina može djelomično biti uslijed lokalne inhibicije crijevnog SGLT1 (važan crijevni transporter glukoze), vezano uz prolazno visoke koncentracije kanagliflozina u crijevnom lumenu prije apsorpcije lijeka (kanagliflozin je niskopotentni inhibitor SGLT1 transportera).
For patients receiving canagliflozin, in case of intercurrent conditions that may lead to volume depletion (such as a gastrointestinal illness), careful monitoring of volume status (e.g., physical examination, blood pressure measurements, laboratory tests including renal function tests), and serum electrolytes is recommended. 
Za bolesnike koji uzimaju kanagliflozin, u slučaju interkurentnih stanja koja mogu dovesti do deplecije volumena (poput gastrointestinalne bolesti), preporučuje se pažljivo praćenje stanja volumena (npr. tjelesni pregledi, mjerenja krvnog tlaka, laboratorijska ispitivanja uključujući ispitivanja bubrežne funkcije) i elektrolita u serumu.
Metabolism and nutrition disorders very common 
Poremećaji metabolizma i prehrane vrlo često
Protein binding is independent of canagliflozin plasma concentrations. 
Vezanje na proteine je neovisno o koncentraciji kanagliflozina u plazmi.
A pre-specified interim meta-analysis was conducted of adjudicated major cardiovascular events in the phase 2 and 3 clinical studies in 9,632 patients with type 2 diabetes, including 4,327 patients (44.9%) with cardiovascular disease or at high risk for cardiovascular disease who are participating in an ongoing cardiovascular study. 
Unaprijed planirana prijevremena meta-analiza provedena je s definiranim velikim kardiovaskularnim događajima iz ispitivanja faze 2 i 3 u 9632 bolesnika s dijabetesom tipa 2, uključujući 4327 bolesnika (44,9%) s kardiovaskularnim bolestima ili s visokim rizikom za kardiovaskularne bolesti, koji su sudjelovali u kardiovaskularnom ispitivanju koje je bilo u tijeku.
Canagliflozin is an orally-active inhibitor of SGLT2. 
Kanagliflozin je oralno djelujući inhibitor SGLT2.
• The active substance is canagliflozin. 
• Djelatna tvar je kanagliflozin.
This may affect your ability to drive, cycle, and use any tools or machines. 
Ovo može utjecati na Vašu sposobnost upravljanja vozilima, biciklom ili sposobnost upotrebe bilo kakvih alata i strojeva.
Due to volume depletion, generally small mean decreases in eGFR were seen within the first 6 weeks of treatment initiation with canagliflozin. 
Zbog deplecije volumena, obično je primjećeno malo smanjenje srednje vrijednosti eGFR tijekom prvih 6 tjedana nakon početka liječenja kanagliflozinom.
Male and female patients with a history of genital mycotic infections were more likely to develop an infection. 
I u muških i ženskih bolesnika s genitalnim gljivičnim infekcijama u anamnezi, infekcije su se češće razvijale.
Canagliflozin did not increase the incidence of tumours in male and female mice in a 2-year study at doses of 10, 30, and 100 mg/kg. 
Kanagliflozin nije povisio incidenciju tumora u mužjaka i ženki miševa u 2-godišnjem ispitivanju pri dozama od 10, 30, i 100 mg/kg.
< 60 mL/min/1.73 m2, and patients ≥ 75 years of age had generally higher incidences of these adverse reactions. 
do < 60 mL/min/1,73 m i bolesnici starosti ≥ 75 godina imali su općenito veće incidencije ovih nuspojava.
If interrupted, consideration should be given to more frequent glucose monitoring. 
Ukoliko je liječenje prekinuto, u obzir treba uzeti čest nadzor glukoze.
Adverse reactions in table 1 are based on the pooled analysis of the four 26-week placebo-controlled studies (n = 2,313) described above. 
Nuspojave u tablici 1 temelje se na analizi udruženih podataka iz četiri 26-tjedna placebom kontrolirana ispitivanja (n = 2313) opisana iznad.
Polyuria or Pollakiuriaf, Urinary tract infection (pyelonephritis and urosepsis have been reported postmarketing) 
Poliurija ili polakizurijaf, infekcija mokraćnog sustava (pijelonefritis i urosepsa prijavljeni nakon stavljanja lijeka u promet)
Experience in New York Heart Association (NYHA) class III is limited, and there is no experience in clinical studies with canagliflozin in NYHA class IV. 
Iskustvo s klasifikacijom New York Heart Associaton (NYHA) III je ograničeno, a nema iskustva u kliničkim ispitivanjima s kanagliflozinom u klasifikaciji NYHA IV. Laboratorijski nalazi mokraće
• carbamazepine, phenytoin, or phenobarbital (medicines used to control seizures) 
• karbamazepin, fenitoin ili fenobarbital (lijekovi koji se uzimaju za kontrolu napadaja)
Increases in urinary glucose excretion with Invokana can falsely lower 1,5-anhydroglucitol (1,5-AG) levels and make measurements of 1,5-AG unreliable in assessing glycemic control. 
Povišenja ekskrecije glukoze urinom uz lijek Invokana mogu lažno sniziti razine 1,5-anhidroglucitola (1,5-AG) te mjerenja 1,5-AG učiniti nepouzdanima u procjeni kontrole glikemije.
Therefore, 1,5-AG assays should not be used for assessment of glycemic control in patients on canagliflozin. 
Stoga se 1,5-AG testovi ne smiju koristiti u svrhu procjene kontrole glikemije u bolesnika na kanagliflozinu.
Canagliflozin's action to increase UGE directly lowering plasma glucose is independent of insulin. 
Djelovanje kanagliflozina na povišenje UGE izravno smanjujući glukozu u plazmi neovisno je o inzulinu.
A total of 714 patients ≥ 55 years of age to ≤ 80 years of age (227 patients 65 years of age to < 75 years of age and 46 patients 75 years of age to ≤ 80 years of age) with inadequate glycaemic control on current diabetes treatment (glucose-lowering medicinal products and/or diet and exercise) participated in a double-blind, placebo-controlled study over 26 weeks. 
Ukupno 714 bolesnika starosti ≥ 55 godina do ≤ 80 godina (227 bolesnika starosti 65 godina do < 75 godina i 46 bolesnika starosti 75 godina do ≤ 80 godina) s neprikladnom regulacijom glikemije s trenutnim liječenjem dijabetesa (lijekovi koji snižavaju glukozu i/ili dijeta i vježba) sudjelovalo je u dvostruko slijepom, placebo-kontroliranom ispitivanju kroz 26 tjedana.
In the dedicated cardiovascular study and the larger pooled analysis, discontinuations due to adverse reactions related to volume depletion and serious adverse reactions related to volume depletion were not increased with canagliflozin. 
U ciljanom kardiovaskularnom ispitivanju i većoj analizi udruženih podataka, prekidi liječenja zbog nuspojava povezanih s deplecijom volumena i zbog ozbiljnih nuspojava povezanih s deplecijom volumena, nisu porasli uz kanagliflozin.
Pharmacotherapeutic group: Drugs used in diabetes, other blood glucose lowering drugs, excluding insulins. 
Farmakoterapijska skupina: Lijekovi za liječenje dijabetesa, ostali lijekovi za sniženje glukoze u krvi, isključujući inzuline.
Canagliflozin 100 mg and 300 mg as monotherapy and as dual or triple add-on therapy resulted in statistically significant reductions in the percentage of body weight at 26 weeks relative to placebo. 
Kanagliflozin od 100 mg i 300 mg kao monoterapija i kao dodatna dvojna i trojna terapija dovela je do statistički značajnih postotaka smanjenja tjelesne težine u 26 tjedana, u odnosu na placebo.
The safety and efficacy of canagliflozin in patients with type 1 diabetes have not been established and canagliflozin should not be used for treatment of patients with type 1 diabetes. 
Sigurnost i djelotvornost kanagliflozina u bolesnika sa šećernom bolešću tipa 1 nisu ustanovljene te se kanagliflozin ne smije primjenjivati u liječenju bolesnika sa šećernom bolešću tipa
These increases in canagliflozin exposure are not expected to be clinically relevant. 
Ne očekuje se da će ova povišenja izloženosti kanagliflozinu biti klinički značajna.
Invokana can be used by itself or along with other medicines you may be using to treat your type 2 diabetes (such as metformin, insulin, a DPP-4 inhibitor [such as sitagliptin, saxagliptin, or linagliptin], a sulphonylurea [such as glimepiride or glipizide], or pioglitazone) that lower blood sugar levels. 
Invokana se može uzimati sama ili zajedno s drugim lijekovima koje možete uzimati za liječenje šećerne bolesti tipa 2 (poput metformina, inzulina, DPP-4 inhibitora [poput sitagliptina, saksagliptina, ili linagliptina], sulfonilureje [poput glimepirida ili glipizida], ili pioglitazona) koji snižavaju razinu šećera u krvi.
d Canagliflozin as add-on therapy to insulin (with or without other glucose-lowering medicinal products). 
d Kanagliflozin kao dodatna terapija s inzulinom (sa ili bez drugih lijekova koji snižavaju glukozu).
INFORMATION IN BRAILLE invokana 100 mg invokana 300 mg 
16. PODACI NA BRAILLEOVOM PISMU invokana 100 mg invokana 300 mg
Before initiating canagliflozin, factors in the patient history that may predispose to ketoacidosis should be considered. 
Prije početka liječenja kanagliflozinom, potrebno je u anamnezi bolesnika razmotriti moguće predisponirajuće faktore za ketoacidozu.
• if you experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat, contact a doctor or the nearest hospital straight away. 
• ako iskusite nagli gubitak tjelesne težine, osjećaj mučnine ili povraćanje, bol u trbuhu, prekomjernu žeđ, ubrzano i duboko disanje, smetenost, neuobičajenu pospanost ili umor, zadah slatkog mirisa, slatki ili metalni okus u ustima ili drugačiji miris mokraće ili znoja, odmah se javite liječniku ili u najbližu bolnicu.
• feeling thirsty 
• osjećaj žeđi • mučnina
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. 
Ako Vam je liječnik rekao da imate bolest nepodnošenja nekih šećera, prije nego što počnete uzimati ovaj lijek posavjetujete se sa svojim liječnikom.
Dabigatran: The effect of concomitant administration of canagliflozin (a weak P-gp inhibitor) on dabigatran etexilate (a P-gp substrate) has not been studied. 
Dabigatran: Učinak konkomitantne primjene kanagliflozina (slabi P-gp inhibitor) na dabigatran eteksilat (P-gp supstrat) nije ispitan.
Urinary uric acid excretion was transiently increased by canagliflozin (increased by 19% compared to baseline on day 1 and then attenuating to 6% on day 2 and 1% on day 13). 
Kanagliflozin je prolazno povisio izlučivanje mokraćne kiseline mokraćom (povišeno za 19% u usporedbi s početnom vrijednošću na dan 1, smanjujući se na 6% na dan 2 i 1% na dan 13).
However, dizziness or lightheadedness has been reported, which may affect your ability to drive, cycle, or use tools or machines. 
Međutim, prijavljene su omaglica i ošamućenost, koji mogu imati utjecaja na Vašu sposobnost upravljanja vozilima, biciklom i upotrebe alata ili strojeva.
Following administration of a single oral [14C]canagliflozin dose to healthy subjects, 41.5%, 7.0%, and 
Nakon primjene jedne oralne doze [14C]kanagliflozina u zdravih ispitanika, 41,5%; 7,0% i 3,2%
The mean steady-state volume of distribution of canagliflozin following a single intravenous infusion in healthy subjects was 119 litres, suggesting extensive tissue distribution. 
Srednja vrijednost volumena distribucije kangliflozina u stanju dinamičke ravnoteže nakon jedne intravenske infuzije u zdravih ispitanika bila je 119 litara, što ukazuje na opsežnu distribuciju u tkiva.
Following co-administration of canagliflozin with rifampicin (an inducer of various active transporters and drug-metabolising enzymes), 51% and 28% decreases in canagliflozin systemic exposure (AUC) and peak concentration (Cmax) were observed. 
Nakon istovremene primjene kanagliflozina s rifampicinom (induktor različitih aktivnih transportera i enzima koji metaboliziraju lijekove), primijećeno je smanjenje sistemske izloženosti kanagliflozinu (AUC) i vršne koncentracije (Cmax) od 51% i 28%.
Canagliflozin showed no effects on fertility and early embryonic development in the rat at exposures up to 19 times the human exposure at the maximum recommended human dose (MRHD). 
Kanagliflozin nije pokazao učinak na plodnost i rani embrionalni razvoj u štakora pri ekspozicijama 19 puta maksimalno dozvoljenih doza u ljudi (MRHD od engl. maximum recommended human dose).
Canagliflozin increased the incidence of testicular Leydig cell tumours in male rats at all doses tested (10, 30, and 100 mg/kg); the lowest dose of 10 mg/kg is approximately 1.5 times the clinical dose of 300 mg based on AUC exposure. 
Kanagliflozin je povisio incidenciju tumora Leydigovih stanica testisa u mužjaka štakora pri svim ispitanim dozama (10, 30 i 100 mg/kg); najniža doza od 10 mg/kg je približno 1,5 puta kliničke doze od 300 mg na temelju izloženosti AUC.
O-glucuronidation is the major metabolic elimination pathway for canagliflozin, which is mainly glucuronidated by UGT1A9 and UGT2B4 to two inactive O-glucuronide metabolites. 
O-glukuronidacija je glavni metabolički put eliminacije za kanagliflozin, koji većinom prolazi glukuronidaciju putem UGT1A9 i UGT2B4 u dva neaktivna O-glukuronidna metabolita.
In a pre- and postnatal development study, canagliflozin administered to female rats from gestation day 6 to lactation day 20 resulted in decreased body weights in male and female offspring at maternally toxic doses > 30 mg/kg/day (exposures ≥ 5.9 times the human exposure to canagliflozin at the MHRD). 
U pre- i postnatalnom razvojnom ispitivanju, kanagliflozin primijenjen ženkama štakora od gestacijskog dana 6 do dana dojenja 20 rezultiralo je smanjenim tjelesnim težinama i muške i ženske maldunčadi pri toksičnim dozama za majku > 30 mg/kg/dan (izloženosti ≥ 5,9 puta izloženosti kanagliflozinu u ljudi pri MHRD).
Canagliflozin is transported by P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). 
Kanagliflozin prenosi P-glikoprotein (P-gp) i protein otpornosti na rak dojke (BCRP, od engl.
10 x 1 film-coated tablets 30 x 1 film-coated tablets 90 x 1 film-coated tablets 100 x 1 film-coated tablets 
10 x 1 filmom obložena tableta 30 x 1 filmom obložena tableta 90 x 1 filmom obložena tableta 100 x 1 filmom obložena tableta
• low blood sugar levels (hypoglycaemia) - when taking this medicine with insulin or a sulphonylurea (such as glimepiride or glipizide). 
• niske razine šećera u krvi (hipoglikemija) - kad se ovaj lijek uzima s inzulinom ili sulfonilurejom (poput glimepirida ili glipizida).
There are no data from the use of canagliflozin in pregnant women. 
Nema podataka o primjeni kanagliflozina u trudnica.
Genital mycotic infections 
Genitalne gljivične infekcije
See the package leaflet for further information. 
Vidjeti Uputu o lijeku za dodatne informacije.
Cholestyramine may potentially reduce canagliflozin exposure. 
Kolestiramin potencijalno može dovesti do smanjenja izloženosti kanagliflozinu.
To assess risk factors for these adverse reactions, a larger pooled analysis (N = 9,439) of patients from eight controlled phase 3 studies including both doses of canagliflozin was conducted. 
U svrhu procjene faktora rizika za te nuspojave, provedena je veća analiza udruženih podataka (N = 9439) bolesnika iz osam kontroliranih ispitivanja faze 3 uključujući obje doze kanagliflozina.
• if you are allergic to canagliflozin or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati lijek Invokana • ako ste alergični na kanagliflozin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
No effects on fertility were observed in animal studies (see section 5.3). 
U ispitivanjima na životinjama nije zamijećeno djelovanje na plodnost (vidjeti dio 5.3).
Lactose intolerance 
Nepodnošenje laktoze
Dizziness postural*, Syncope* 
Posturalna omaglica*, sinkopa*
EU/1/13/884/001 (100 mg - 10 tablets) EU/1/13/884/002 (100 mg - 30 tablets) EU/1/13/884/003 (100 mg - 90 tablets) EU/1/13/884/004 (100 mg - 100 tablets) EU/1/13/884/005 (300 mg - 10 tablets) EU/1/13/884/006 (300 mg - 30 tablets) EU/1/13/884/007 (300 mg - 90 tablets) EU/1/13/884/008 (300 mg - 100 tablets) 
EU/1/13/884/001 (100 mg - 10 tableta) EU/1/13/884/002 (100 mg - 30 tableta) EU/1/13/884/003 (100 mg - 90 tableta) EU/1/13/884/004 (100 mg - 100 tableta) EU/1/13/884/005 (300 mg - 10 tableta) EU/1/13/884/006 (300 mg - 30 tableta) EU/1/13/884/007 (300 mg - 90 tableta) EU/1/13/884/008 (300 mg - 100 tableta)
Vulvovaginal candidiasis**, g common 
Vulvovaginalna kandidijaza**,g često
Canagliflozin is not recommended for use in patients receiving loop diuretics (see section 4.5) or who are volume depleted, e.g., due to acute illness (such as gastrointestinal illness). 
Ne preporučuje se primjena kanagliflozina u bolesnika koji uzimaju diuretike Henleove petlje (vidjeti dio 4.5), ili u onih koji imaju depleciju volumena, npr. zbog akutne bolesti (poput gastrointestinalne bolesti).
Haematocrit increase was observed with canagliflozin treatment (see section 4.8); therefore, caution in patients with already elevated haematocrit is warranted. 
Tijekom liječenja kanagliflozinom uočeno je povišenje hematokrita (vidjeti dio 4.8); stoga, nalaže se oprez u bolesnika čiji je hematokrit već povišen.
In addition, reductions in body weight and systolic blood pressure relative to placebo were observed. 
Dodatno, u odnosu na placebo uočena su smanjenja tjelesne težine i sistoličkog krvnog tlaka.
Balanitis or balanoposthitis occurred primarily in uncircumcised male patients. 
Javili su se balanitis ili balanopostitis, naročito u neobrezanih muških bolesnika.
In controlled clinical studies of canagliflozin, increases in adverse reactions related to volume depletion (e.g., postural dizziness, orthostatic hypotension, or hypotension) were seen more commonly with the 300 mg dose and occurred most frequently in the first three months (see section 4.8). 
U kontroliranim kliničkim ispitivanjima kanagliflozina, povećanje nuspojava povezanih s deplecijom volumena (npr. posturalna omaglica, ortostatska hipotenzija, hipotenzija) češće je primijećeno uz dozu od 300 mg i češće su zabilježene u prva tri mjeseca (vidjeti dio 4.8).
The tablet is yellow, capsule-shaped, approximately 11 mm in length, immediate-release and film-coated, with “CFZ” on one side and “100” on the other side. 
Tableta je žute boje, oblika kapsule, duljine približno 11 mm, s trenutnim oslobađanjem i filmom obložena, s “CFZ” na jednoj strani i “100” na drugoj strani.
Enterohepatic circulation of canagliflozin was negligible. 
Enterohepatička cirkulacija kanagliflozina bila je zanemariva.
The effect of canagliflozin on fertility in humans has not been studied. 
Djelovanje kanagliflozina na plodnost u ljudi nije ispitano.
Due to its mechanism of action, patients taking canagliflozin will test positive for glucose in their urine. 
Zbog mehanizma djelovanja, bolesnici koji uzimaju kanagliflozin imati će pozitivan nalaz glukoze u mokraći.
The pack sizes are cartons of 10 x 1, 30 x 1, 90 x 1, or 100 x 1 tablets. 
Veličine pakiranja su kutije s 10 x 1, 30 x 1, 90 x 1 ili 100 x 1 tableta.
• The starting dose of Invokana is one 100 mg tablet each day. 
Koliko uzeti • Početna doza lijeka Invokana je jedna tableta od 100 mg svaki dan.
The tablet is white, capsule-shaped, approximately 17 mm in length, immediate-release and film-coated, with “CFZ” on one side and “300” on the other side. 
Tableta je bijele boje, oblika kapsule, duljine približno 17 mm, s trenutnim oslobađanjem i filmom obložena, s “CFZ” na jednoj strani i “300” na drugoj strani.
Consistent with the mechanism of sodium glucose co-transporter 2 (SGLT2) inhibition with increased UGE, vulvovaginal candidiasis in females and balanitis or balanoposthitis in males were reported in clinical trials (see section 4.8). 
Sukladno mehanizmu inhibicije kotransportera natrij glukoza 2 (SGLT2) s porastom UGE, u kliničkim ispitivanjima prijavljena je vulvovaginalna kandidijaza u žena, a u muškaraca balanitis ili balanopostitis (vidjeti dio 4.8).
After single-dose oral administration of 100 mg and 300 mg in healthy subjects, canagliflozin was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1 hour to 2 hours post-dose. 
Nakon primjene jedne oralne doze od 100 mg i 300 mg, u zdravih ispitanika, kanagliflozin se brzo apsorbirao, uz pojavu vršnih koncentracija (medijan Tmax) 1 sat do 2 sata nakon uzimanja doze.
Overall, 0.5% of male patients discontinued canagliflozin due to candidial balanitis or balanoposthitis. 
Općenito, 0,5% muških bolesnika prekinulo je uzimanje kanagliflozina zbog kandidnog balanitisa ili balanopostitisa.
Consistent with the expected increase of hypoglycaemia when a medicinal product not associated with hypoglycaemia is added to insulin and/or sulphonylurea, an increase in hypoglycaemia episodes/events was seen when canagliflozin was added to insulin and/or a sulphonylurea (see section 4.8). 
U skladu s očekivanim porastom hipoglikemije kad se lijek koji nije povezan s hipoglikemijom dodaje inzulinu i/ili sulfonilureji, zabilježen je porast epizoda/događaja hipoglikemije kad je kanagliflozin dodan inzulinu i/ili sulfonilureji (vidjet dio 4.8).